MYSZ
My Size, Inc.
$0.5300
+1.34%
$2.6M
No data for this timeframe.
Vol
Market Cap$2.6M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$386.00
Inst. Activity0 buys / 1 sells
SEC Reports3
Recent Activity
Jun 2, 2026
SEC
My Size, Inc. filed additional definitive proxy soliciting materials (DEFA14A) on June 2, 2026. The filing is a routine
DEFA14A — Impact 2/10
May 15, 2026
SEC
My Size, Inc. reported Q1 2026 revenue of $2.39M, up 62% YoY from $1.48M, with gross margin expanding to 39.3% from 28.4
8-K — Impact 5/10
Mar 3, 2026
SEC
My Size, Inc. reported preliminary 2025 revenue of approximately $10 million, with its core Orgad business generating st
8-K — Impact 6/10
Inst.
MORGAN STANLEY — NEAR_EXIT
509 shares ($386.00)
Inst.
UBS Group AG — DOUBLED
39,332 shares ($46.8K)
Price Targets
Historical data — last covering-analyst action Nov 2024. No current recommendation available.
$3.00 (Nov 2024)
Current $0.4900
Low $3.00
Median $3.00
High $3.00
1 analysts
$3.00
$3.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Aug 21, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 21, 2023 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Aug 15, 2023 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 17, 2023 | HC Wainwright & Co. | REITERATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-2.70 | $-2.70 — $-2.70 | -48% YoY | 1 |
Latest Reports
NEUTRAL
DEFA14A
2/10
My Size, Inc. filed additional definitive proxy soliciting materials (DEFA14A) on June 2, 2026. The filing is a routine
Jun 2, 2026
NEUTRAL
8-K
5/10
My Size, Inc. reported Q1 2026 revenue of $2.39M, up 62% YoY from $1.48M, with gross margin expanding to 39.3% from 28.4
May 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $386.00 | NEAR_EXIT |
1 institutional holders with $386.00 total value (509 shares) as of 2025-Q4. Top holders: MORGAN. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 509 | $386.00 | 100.0% | NEAR_EXIT -93.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | NEAR_EXIT | 7,457 | 509 | -93.2% | $386.00 | 2025-Q4 |
| UBS Group AG | DOUBLED | 17,147 | 39,332 | +129.4% | $46.8K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 509 | 7,457 | +1365.0% | $8.9K | 2025-Q3 |
| UBS Group AG | NEW | — | 16,785 | — | $71.7K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
DEFA14A
2/10
My Size, Inc. filed additional definitive proxy soliciting materials (DEFA14A) on June 2, 2026. The
Jun 2, 2026
NEUTRAL
8-K
5/10
My Size, Inc. reported Q1 2026 revenue of $2.39M, up 62% YoY from $1.48M, with gross margin expandin
May 15, 2026
MIXED
8-K
6/10
My Size, Inc. reported preliminary 2025 revenue of approximately $10 million, with its core Orgad bu
Mar 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Nov 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2024. No current recommendation available.
$3.00 mean target (Nov 2024)
$3.00 Low
$3.00 High
| Metric | Value |
|---|---|
| Current Price | $0.4900 |
| Target Low | $3.00 |
| Target Mean | $3.00 |
| Target Median | $3.00 |
| Target High | $3.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$-2.70 | $-2.70 | $-2.70 | -48.4% | — | — | $0.0B | 38.9% | 1 |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 21, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 15, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 17, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.